Skip to content
Open access

Empagliflozin and 12-Month Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: A Prospective Observational Cohort Study in Pakistan

Oct 2026 · Pakistan Heart Journal · 0 citations · 11 references

TL;DR

In this prospective observational cohort of Pakistani adults with HFpEF, empagliflozin 10 mg once daily added to standard heart failure therapy was associated with a significantly lower hazard of first HF hospitalization, slower deterioration in renal function, and greater improvement in health-related quality of life over 12 months.

Abstract

Objectives: To evaluate the association of empagliflozin 10 mg once daily with first heart failure (HF) hospitalization among Pakistani adults with heart failure with preserved ejection fraction (HFpEF), and to assess its associations with cardiovascular mortality, renal function, health-related quality of life, and safety during 12 months of follow-up. Methodology: This prospective, single-center observational cohort study included 400 adults with symptomatic HFpEF enrolled at the Karachi Institute of Heart Diseases. Participants were categorized into an empagliflozin group (n=200), receiving empagliflozin 10 mg/day in addition to standard heart failure therapy, and a control group (n=200), receiving standard therapy without an SGLT2 inhibitor. Treatment allocation was non-randomized and reflected routine clinical prescribing. Definite HFpEF was defined by LVEF ≥50%, NYHA class II–IV symptoms, elevated NT-proBNP, and echocardiographic evidence of structural and/or diastolic dysfunction. The primary outcome was first unplanned HF hospitalization during 12 months. Secondary outcomes included all-cause mortality, change in eGFR, and KCCQ-12 score. Results: 5 patients (2.5%) in the empagliflozin group and 7 (3.5%) in the control group lost to follow-up. First HF hospitalization occurred in 36 patients (18.0%) in empagliflozin compared with 60 patients (30.0%) in the control group. After multivariable adjustment, empagliflozin use was associated with a lower hazard of first HF hospitalization (adjusted HR 0.58, 95% CI 0.39–0.86; p=0.007). Cardiovascular mortality occurred in 12 (6.0%) versus 18 (9.0%) patients, respectively, with no statistically significant between-group association (adjusted HR 0.67, 95% CI 0.32–1.39; p=0.28). The annualized eGFR slope was −2.5 mL/min/1.73 m²/year in the empagliflozin group compared with −6.4 mL/min/1.73 m²/year in controls, with an adjusted between-group difference at 12 months of +3.9 mL/min/1.73 m² (95% CI 2.1–5.7; p<0.001). KCCQ-12 scores improved by +8.7 points with empagliflozin compared with +1.9 points in controls, corresponding to an adjusted between-group difference of +5.8 points (95% CI 3.2–8.4; p<0.001). Conclusion: In this prospective observational cohort of Pakistani adults with HFpEF, empagliflozin 10 mg once daily added to standard heart failure therapy was associated with a significantly lower hazard of first HF hospitalization, slower deterioration in renal function, and greater improvement in health-related quality of life over 12 months.

Read PDF

Similar papers

Open access Oct 2026

Dapagliflozin’s impact on health-related quality of life and mortality in patients of chronic heart failure with reduced ejection fraction: a randomized controlled trial

Objective: To explore the impact of dapagliflozin on health-related quality of life, functional status and mortality in chronic heart failure with reduced ejection fraction patients. Method: The randomized controlled trial was conducted from April 2023 to May 2024 at the Department of Pharmacology and Therapeutics, Arm...

S. Rafique, Kulsoom Farhat, Mudassar Noor et al. · 0 citations
Open access Oct 2026

Clinical outcomes and safety of finerenone in patients with heart failure: a real-world observational study in China

Finerenone is a highly selective nonsteroidal mineralocorticoid receptor antagonist, but data on its use in patients with heart failure (HF) in real-world clinical practice remain limited. This study evaluated longitudinal clinical changes and safety outcomes observed during finerenone treatment in patients with HF...

Cui-Mei Zhao, Bing Sun, Hui-Feng Xu et al. · 0 citations
Open access Oct 2026

The LIRA-HF trial: liraglutide in heart failure with reduced ejection fraction and obesity – a 30-month randomized trial

GLP-1 receptor agonists reduce cardiovascular events in type 2 diabetes, but their role in heart failure with reduced ejection fraction (HFrEF) remains controversial due to concerns over heart rate elevation and potential arrhythmogenicity observed in prior trials. To evaluate whether liraglutide added to...

R. R. Sabido, M. Lagunas, Y. Jiménez et al. · 0 citations
Open access Oct 2026

Baseline characteristics of patients with HFrEF on dapagliflozin: final analysis of baseline data from the EVOLUTION-HF DEallEF study HFrEF cohort

Heart failure (HF) is one of the leading public health challenges worldwide. Standard pharmacological HF management combines different drug classes based on the underlying phenotype and left ventricular ejection fraction (LVEF). In HF with reduced LVEF (HFrEF), the guideline-directed therapy should include renin-...

B. Assmuss, A. Guth, B. Subin et al. · 0 citations
Open access Oct 2026

Statin treatment long-term prognostic impact and its association with immune-inflammatory biomarkers levels in acute heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction (HFpEF) is characterized by diastolic dysfunction of left ventricle. There is evidence on the role of inflammation in the pathophysiology of HFpEF, however this knowledge is yet to be utilized in clinical practice. We conducted a study to evaluate the associat...

K. Stepien, P. Rostoff, A. Karcińska et al. · 0 citations
Oct 2026

Clinical outcomes of carvedilol versus metoprolol in patients with heart failure with preserved ejection fraction following myocardial infarction

Optimal beta-blocker selection in patients with heart failure with preserved ejection fraction (HFpEF) following acute myocardial infarction (MI) remains uncertain. While both carvedilol and metoprolol are commonly prescribed, comparative effectiveness data in HFpEF are limited. We evaluated 3-year cardiovascular...

A. Ajibade, G. Odukudu, D. Dele et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.